Abstract: The present invention relates to at least one novel anti-MCP-1 antibody, including isolated nucleic acids that encode at least one anti-MCP-1 antibody, MCP-1, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.

Abstract: The present invention provides novel methods of treatment of multiple sclerosis and other autoimmune diseases or inflammatory disorders, and antagonists, including isolated binding proteins for use in the novel methods. There is provided a method of treating multiple sclerosis comprising the neutralization of the biological activity of IL-7 by binding to CD127 or IL-7. The isolated binding proteins may also neutralize the biological activity of TSLP.

Abstract: Anti-Respiratory Syncytial Virus (RSV) monoclonal antibodies, RSV F protein antigens and their uses are disclosed.

Abstract: The present invention relates to at least one novel anti-MCP-1 antibody having specific epitopes, including isolated nucleic acids that encode at least one anti-MCP-1 antibody, MCP-1, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.

Abstract: The present invention provides novel methods of treatment of multiple sclerosis and other autoimmune diseases or inflammatory disorders, and antagonists, including isolated binding proteins for use in the novel methods. There is provided a method of treating multiple sclerosis comprising the neutralization of the biological activity of IL-7 by binding to CD127 or IL-7. The isolated binding proteins may also neutralize the biological activity of TSLP.

Abstract: Described and claimed herein are combinatorial synthetic Fab libraries displayed on a phage pIX protein. The libraries were built on scaffolds representing the most frequently used genes in human antibodies, which were diversified to mirror the variability of natural antibodies. After selection using a diverse panel of proteins, numerous specific and high-affinity Fabs were isolated. By a process called in-line maturation the affinity of some antibodies was improved up to one hundred-fold yielding low pM binders suitable for in vivo use. This work thus demonstrates the feasibility of displaying complex Fab libraries as pIX-fusion proteins for antibody discovery and lays the foundations for studies on the structure-function relationship of antibodies.

Abstract: The present invention relates to at least one novel anti-MCP-1 antibody, including isolated nucleic acids that encode at least one anti-MCP-1 antibody, MCP-1, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.

Abstract: A resonant switching power system operates with two resonant frequencies. A first frequency depends on the secondary leakage inductance of an output transformer and capacitor. The first frequency varies with changes in the load because load changes alter the leakage inductance. A second resonant frequency depends on the gate source capacitance of two MOSFET power devices in the circuit and the leakage inductance of the circuit's driving transformer. Power is thereby supplied that is always in phase with the load so that switching in the power supply occurs when current is near zero. High thermal efficiency is thereby achieved.

Abstract: Anti-Respiratory Syncytial Virus (RSV) monoclonal antibodies, RSV F protein antigens and their uses are disclosed.

Abstract: A resonant switching power system operates with two resonant frequencies. A first frequency depends on the secondary leakage inductance of an output transformer and capacitor. The first frequency varies with changes in the load because load changes alter the leakage inductance. A second resonant frequency depends on the gate source capacitance of two MOSFET power devices in the circuit and the leakage inductance of the circuit's driving transformer. Power is thereby supplied that is always in phase with the load so that switching in the power supply occurs when current is near zero. High thermal efficiency is thereby achieved.

Abstract: A retractable badge reel with a billboard designed to display a logo, such that unadorned badge reels can be manufactured separately from the billboards that contain the logos. The billboard is optionally removable, allowing the logo being displayed to be changed without having to produce new retractable badge reels in their entirety. In another embodiment, a billboard designed to display a logo is adapted to be installed over the face of an existing retractable badge reel, such that the logo on the existing unit is hidden and the new logo on the billboard is instead displayed. A casement comprising the billboard and a back housing member have a mating portion that mates with a bob mating portion of a bob attached to the exterior end of the retractable cord to prevent the bob from shifting or twisting when the cord is in the retracted position.

Abstract: A retractable badge reel with a billboard designed to display a logo, such that unadorned badge reels can be manufactured separately from the billboards that contain the logos. The billboard is optionally removable, allowing the logo being displayed to be changed without having to produce new retractable badge reels in their entirety. In another embodiment, a billboard designed to display a logo is adapted to be installed over the face of an existing retractable badge reel, such that the logo on the existing unit is hidden and the new logo on the billboard is instead displayed. A casement comprising the billboard and a back housing member have a mating portion that mates with a bob mating portion of a bob attached to the exterior end of the retractable cord to prevent the bob from shifting or twisting when the cord is in the retracted position.

Abstract: Human Mindin polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing Human Mindin polypeptides and polynucleotides in therapy, and diagnostic assays for such.

Abstract: R35 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing R35 polypeptides and polynucleotides in diagnostic assays.

Abstract: An apparatus and electrical circuit utilizing a high power Class “D” type amplifier for delivering an audio signal to a acoustic transducer system. A PWM modulator, the output of which is inhibited during power fluctuations or in absence of an audio input, converts a suitably conditioned audio input signal into low power, high frequency positive and negative components 180 degrees out of phase. A PWM signal power amplifier stage and low pass filters amplify the signal components, remove the higher PWM switching carrier frequency and pass the results to a power audio transformer impedance matched to the output acoustic transducers. Feedback signals are taken from the power stage before the low pass filters, suitably conditioned and combined as negative feedback with the input analog audio signal to minimize output distortion and maintain correct audio output voltage with changing load impedance and power supply voltages.

Abstract: R35 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing R35 polypeptides and polynucleotides in diagnostic assays.

Abstract: Rat EDG6 polypeptides and polynucleotides and method for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for screening for compounds that either agonize or antagonize rat EDG6. Such compounds are expected to be useful in treatment of human diseases, including, but not limited to: infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; diabetes, obesity; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; stroke; ulcers; asthma; allergies; benign prostatic hypertrophy; migraine; vomiting; psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, depression, delirium, dementia, and severe mental retardation; and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome.

Abstract: EDG1 (mouse) polypeptides and polynucleotides and methods for producng such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing EPDG1 (mouse) polypeptides and polynucleotides in therapy, and diagnostic assays for such.

Abstract: Mus musculus EDG4 polypeptides and polynucleotides and method for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for screening for compounds that either agonize or antagonize Mus musculus EDG4. Such compounds are expected to be useful in treatment of human diseases, including, but not limited to: infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; diabetes, obesity; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; stroke; ulcers; asthma; allergies; benign prostatic hypertrophy; migraine; vomiting; psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, depression, delirium, dementia, and severe mental retardation; and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome.

Abstract: Mus musculus EDG7 polypeptides and polynucleotides and method for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for screening for compounds that either agonize or antagonize Mus musculus EDG7. Such compounds are expected to be useful in treatment of human diseases, including, but not limited to: infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; diabetes, obesity; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; stroke; ulcers; asthma; allergies; benign prostatic hypertrophy; migraine; vomiting; psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, depression, delirium, dementia, and severe mental retardation; and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome.